The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis

International Urology and Nephrology

Volumn 47, Issue 3, 2015, Pages 537-549

  Sarathy, Harini ^a   Pramanik, Vedatrayee ^a   Kahn, Jared ^b   Abramowitz, Matthew K ^a   Meier, Kristen ^a   Kishore, Preeti ^a   Melamed, Michal L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Dialysis; Insulin resistance; Intervention studies; Meta analysis; Vitamin D

Indexed keywords

CALCITRIOL; CINACALCET; COLECALCIFEROL; DIHYDROTACHYSTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PARATHYROID HORMONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT; GLUCOSE BLOOD LEVEL;

AGE; ARTICLE; BODY HEIGHT; BODY WEIGHT; DIABETIC PATIENT; DIET RESTRICTION; END STAGE RENAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HEMODIALYSIS PATIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DISEASE; META ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; METABOLISM; TIME;

BLOOD GLUCOSE; BONE DENSITY CONSERVATION AGENTS; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL DIALYSIS; TIME FACTORS; VITAMIN D;

EID: 84925521841     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-0909-0     Document Type: Article

References (42)

1. Singh B, Saxena A (2010) Surrogate markers of insulin resistance: a review. World J Diabetes 1(2):36–47
2. de Boer IH (2008) Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens 17(6):566–572
3. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E (1998) Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53(5):1343–1347
4. Hung AM, Ikizler TA (2011) Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol 171:127–134
5. Jones G (2007) Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 20(4):316–324
6. Holick MF (2007) Vitamin D deficiency. New Engl J Med 357(3):266–281
7. Maestro B, Campion J, Davila N, Calle C (2000) Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47(4):383–391
8. Norman AW, Frankel JB, Heldt AM, Grodsky GM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209(4458):823–825
9. Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Ren Physiol 289(1):F8–F28
10. Sergeev IN, Rhoten WB (1995) 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 136(7):2852–2861
11. Mak RH (1992) Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41(4):1049–1054
12. Mak RH (1992) Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 6(4):345–348
13. Mak RH (1998) 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53(5):1353–1357
14. Hung AM, Sundell MB, Plotnikova NE, Bian A, Shintani A, Ellis CD, Siew ED, Ikizler TA (2013) A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. J Ren Nutr 23(3):185–193
15. Reeves BC, Deeks JJ, Higgins JPT, Wells GA (2008) Chapter 13: including non-randomized studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.0.1 [updated September 2008]. The cochrane collaboration. www.cochrane-handbook.org
16. Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y, Furukawa TA (2014) Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Med Res Methodol 14:30. doi:10.2286/1471-2288-14-30
17. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
19. Deeks JJ, Higgins JPT, Altman DG (2008) Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The cochrane collaboration. www.cochrane-handbook.org
20. Furlan AD, Pennick V, Bombardier C, van Tulder M (2009) Editorial Board CBRG: 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 34(18):1929–1941
21. Lind L, Lithell H, Wengle B, Wrege U, Ljunghall S (1988) A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure. Scand J Urol Nephrol 22(3):219–222
22. Quesada JM, Martin-Malo A, Santiago J, Hervas F, Martinez ME, Castillo D, Barrio V, Aljama P (1990) Effect of calcitriol on insulin secretion in uraemia. Nephrol Dial Transpl 5(12):1013–1017
23. Turk S, Yeksan M, Tamer N, Gurbilek M, Erdogan Y, Erkul I (1992) Effect of 1,25 (OH)2D3 treatment on glucose intolerance in uraemia. Nephrol Dialysis Transpl 7(12):1207–1212
24. Lin SH, Lin YF, Lu KC, Diang LK, Chyr SH, Liao WK, Shieh SD (1994) Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci (Lond) 87(5):533–538
25. Lu KC, Shieh SD, Lin SH, Chyr SH, Lin YF, Diang LK, Li BL, Sheu WH, Ding YA (1994) Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure. Q J Med 87(6):359–365
26. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R (1995) Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 47(1):200–206
27. Gunal AI, Celiker H, Celebi H, Ustundag B, Gunal SY (1997) Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin Nephrol 48(2):109–113
28. Khajehdehi P, Taheri S (2003) Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J Ren Nutr 13(2):78–83
29. Strozecki P, Kretowicz M, Odrowaz-Sypniewska G, Manitius J (2004) The influence of intravenous 1,25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. Ren Fail 26(4):345–348
30. Blair D, Byham-Gray L, Lewis E, McCaffrey S (2008) Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18(4):375–382
31. Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipoor F, Shakeri M (2008) Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients. Saudi J Kidney Dis Transpl 19(6):942–947
32. Ibrahim MA, Sany D, El Shahawy Y, Awdallah A (2012) Effect of activated vitamin D on glucoparameters in HCV seropositive and seronegative patients on chronic hemodialysis. Ren Fail 34(10):1188–1194
33. Ulutas O, Taskapan H, Taskapan MC, Temel I (2013) Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. Int Urol Nephrol 45:879–884
34. Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A (2013) Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 37(3):239–248
35. Palmer SC, Gregor DO, Makaskill P, Craig JC, Elder GJ, Strippoli GFM (2007) Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 147(12):840–853
36. Thompson SG, Higgins JPT (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559–1574
37. De Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J (2013) Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney Int 83(2):323–330
38. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA J Am Med Assoc 307(7):674–684
39. Autier P, Boniol M, Pizot C, Mullie P (2014) Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2(1):76–89
40. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R (2003) Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26(12):3320–3325
41. Abe M, Kaizu K, Matsumoto K (2007) Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther Apher Dial 11(4):280–287
42. Alemzadeh R, Kichler J (2012) Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents. Metab Syndr Relat Disord 10(6):422–429